share_log

天津发展(00882):力生制药全资子公司中央药业接获民事裁定书

Tianjin Development (00882): Central Pharmaceutical, a wholly-owned subsidiary of Lisheng Pharmaceuticals, received a civil ruling

Zhitong Finance ·  Mar 27 18:31

Tianjin Development (00882) issued an announcement. Recently, Tianjin Lisheng Pharmaceutical Co., Ltd., a non-wholly-owned subsidiary of the company...

Zhitong Finance App News, Tianjin Development (00882) issued an announcement. Recently, Tianjin Central Pharmaceutical Co., Ltd. (“Central Pharmaceutical”), a wholly-owned subsidiary of the company's non-wholly-owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) received a civil ruling No. 21 from the Tianjin Higher People's Court (2024). The court decided against Beijing Jinyang Licang Pharmaceutical Co., Ltd. (currently renamed: Beijing Kaianrui Pharmaceutical Management Co., Ltd., hereinafter referred to as “Kaianrui Pharmaceutical”).

The specific ruling results are as follows:

1. Annulment of the Tianjin Second Intermediate People's Court (2023) Tianjin 02 Minchu Civil Judgment No. 298;

2. The case was sent back to Tianjin No. 2 Intermediate People's Court for retrial.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment